274 related articles for article (PubMed ID: 37733107)
1. Advanced Formulation Approaches for Emerging Therapeutic Technologies.
Allahham N; Colic I; Rayner MLD; Gurnani P; Phillips JB; Rahim AA; Williams GR
Handb Exp Pharmacol; 2024; 284():343-365. PubMed ID: 37733107
[TBL] [Abstract][Full Text] [Related]
2. Lipid-based nucleic acid therapeutics with in vivo efficacy.
Sufian MA; Ilies MA
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Mar; 15(2):e1856. PubMed ID: 36180107
[TBL] [Abstract][Full Text] [Related]
3. Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation.
Afonin KA; Dobrovolskaia MA; Ke W; Grodzinski P; Bathe M
Adv Drug Deliv Rev; 2022 Feb; 181():114081. PubMed ID: 34915069
[TBL] [Abstract][Full Text] [Related]
4. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.
Rinoldi C; Zargarian SS; Nakielski P; Li X; Liguori A; Petronella F; Presutti D; Wang Q; Costantini M; De Sio L; Gualandi C; Ding B; Pierini F
Small Methods; 2021 Sep; 5(9):e2100402. PubMed ID: 34514087
[TBL] [Abstract][Full Text] [Related]
6. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
7. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
Milane L; Amiji M
Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
[TBL] [Abstract][Full Text] [Related]
8. What's Next after Lipid Nanoparticles? A Perspective on Enablers of Nucleic Acid Therapeutics.
Das R; Kanjilal P; Medeiros J; Thayumanavan S
Bioconjug Chem; 2022 Nov; 33(11):1996-2007. PubMed ID: 35377622
[TBL] [Abstract][Full Text] [Related]
9. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
[TBL] [Abstract][Full Text] [Related]
10. Advances in delivery methods of
ElFar OA; Billa N; Lim HR; Chew KW; Cheah WY; Munawaroh HSH; Balakrishnan D; Show PL
Bioengineered; 2022 Jun; 13(6):14681-14718. PubMed ID: 35946342
[TBL] [Abstract][Full Text] [Related]
11. Evolution of drug delivery systems: From 1950 to 2020 and beyond.
Park H; Otte A; Park K
J Control Release; 2022 Feb; 342():53-65. PubMed ID: 34971694
[TBL] [Abstract][Full Text] [Related]
12. Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development.
Lu M; Xing H; Zheng A; Huang Y; Liang XJ
Acc Chem Res; 2023 Feb; 56(3):224-236. PubMed ID: 36624086
[TBL] [Abstract][Full Text] [Related]
13. Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines.
Chatzikleanthous D; O'Hagan DT; Adamo R
Mol Pharm; 2021 Aug; 18(8):2867-2888. PubMed ID: 34264684
[TBL] [Abstract][Full Text] [Related]
14. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
Qiu M; Li Y; Bloomer H; Xu Q
Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
[TBL] [Abstract][Full Text] [Related]
15. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.
Fernandes Q; Inchakalody VP; Merhi M; Mestiri S; Taib N; Moustafa Abo El-Ella D; Bedhiafi T; Raza A; Al-Zaidan L; Mohsen MO; Yousuf Al-Nesf MA; Hssain AA; Yassine HM; Bachmann MF; Uddin S; Dermime S
Ann Med; 2022 Dec; 54(1):524-540. PubMed ID: 35132910
[TBL] [Abstract][Full Text] [Related]
16. Current Status and Trends in Nucleic Acids for Cancer Therapy: A Focus on Polysaccharide-Based Nanomedicines.
Molinar C; Tannous M; Meloni D; Cavalli R; Scomparin A
Macromol Biosci; 2023 Sep; 23(9):e2300102. PubMed ID: 37212473
[TBL] [Abstract][Full Text] [Related]
17. Nucleic Acids as Biotools at the Interface between Chemistry and Nanomedicine in the COVID-19 Era.
Borbone N; Piccialli I; Falanga AP; Piccialli V; Roviello GN; Oliviero G
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457177
[TBL] [Abstract][Full Text] [Related]
18. Protein-based nanoparticles for therapeutic nucleic acid delivery.
Eweje F; Walsh ML; Ahmad K; Ibrahim V; Alrefai A; Chen J; Chaikof EL
Biomaterials; 2024 Mar; 305():122464. PubMed ID: 38181574
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery.
Mollé LM; Smyth CH; Yuen D; Johnston APR
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Nov; 14(6):e1809. PubMed ID: 36416028
[TBL] [Abstract][Full Text] [Related]
20. Novel approaches for vaccine development.
Gebre MS; Brito LA; Tostanoski LH; Edwards DK; Carfi A; Barouch DH
Cell; 2021 Mar; 184(6):1589-1603. PubMed ID: 33740454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
